Comprehensive survey of vitiligo patients in the northeast of China using a predesigned questionnaire

To assess the sociodemographic data and clinical information of outpatients affected by vitiligo in the northeast of China, vitiligo patients or guardians who presented to the clinic were invited to participate in an exploratory questionnaire. The questionnaire consisted of two sections related to vitiligo, including sociodemographic data and clinical information. A total of 983 vitiligo patients answered the questionnaire. The rates of female and male patients were comparable. The investigated patients were mostly young and middle‐aged. Most patients suffered from vitiligo in childhood or young adulthood. Vitiligo vulgaris was the most common type of vitiligo in clinic and 53.0% of patients were categorized as body surface area (BSA) of 10% or less. In response to the latest treatment, 43.6% of patients achieved good response (completely stopped or almost disappeared). More patients at active stage showed good response than the patients at stable stage (χ2 = 7.866, P < 0.05). Chronic comorbid condition(s) were observed in 12.6% of patients with BSA of more than 10%, whereas those were seen in 6.0% of patients with BSA of 10% or less (χ2 = 12.969, P < 0.05). In conclusion, active vitiligo seems to respond better than stable vitiligo and complications with other autoimmune diseases more frequently observed in severe patients than mild patients. The current study presented a comprehensive understanding of vitiligo in the northeast of China.

[1]  V. Eleftheriadou Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review ‘Interventions for vitiligo’ 2010 , 2013, The British journal of dermatology.

[2]  H. Nakagawa,et al.  Guidelines for the diagnosis and treatment of vitiligo in Japan , 2013, The Journal of dermatology.

[3]  G. Loussouarn,et al.  Greying of the human hair: a worldwide survey, revisiting the ‘50’ rule of thumb , 2012, The British journal of dermatology.

[4]  S. Kılıç,et al.  Profile of vitiligo patients attending a training and research hospital in Central Anatolia: A retrospective study , 2012, The Journal of dermatology.

[5]  V. Hegyi,et al.  [Methods and means for pigmentation and depigmentation. Sense or nonsense?]. , 2010, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[6]  N. Savaş,et al.  Macrophage migration inhibitory factor in patients with vitiligo and relationship between duration and clinical type of disease , 2010, Clinical and experimental dermatology.

[7]  J. Hegyi,et al.  Methoden und Mittel zur Pigmentierung und Depigmentierung , 2010, Der Hautarzt.

[8]  M. Sprangers,et al.  The burden of vitiligo: patient characteristics associated with quality of life. , 2009, Journal of the American Academy of Dermatology.

[9]  M. Radtke,et al.  Willingness‐to‐pay and quality of life in patients with vitiligo , 2009, The British journal of dermatology.

[10]  A. Mehta,et al.  Clinical and sociodemographic study of vitiligo. , 2008, Indian journal of dermatology, venereology and leprology.

[11]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[12]  C. Archer Disorders of melanocytes , 2008 .

[13]  D. Ashcroft,et al.  Therapeutic interventions for vitiligo. , 2008, Journal of the American Academy of Dermatology.

[14]  L. Ersoy,et al.  Clinical characteristics in 113 Turkish vitiligo patients. , 2008, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[15]  K. Bergstrom,et al.  Vitiligo: nonsurgical treatment options and the evidence behind their use. , 2008, Journal of drugs in dermatology : JDD.

[16]  I. Schaefer,et al.  Benefit Evaluation in Vitiligo Treatment: Development and Validation of a Patient-Defined Outcome Questionnaire , 2008, Dermatology.

[17]  V. Sehgal,et al.  Vitiligo: compendium of clinico-epidemiological features. , 2007, Indian journal of dermatology, venereology and leprology.

[18]  Sheri L. Riccardi,et al.  NALP1 in vitiligo-associated multiple autoimmune disease. , 2007, The New England journal of medicine.

[19]  D. Ashcroft,et al.  Interventions for vitiligo: a Cochrane systematic review , 2006 .

[20]  R. Busse,et al.  Methods for the comparative evaluation of pharmaceuticals , 2005, GMS health technology assessment.

[21]  H. Rusche,et al.  Policy decision making and outcomes research in drug utilization , 2005, Journal of Public Health.

[22]  W. Du,et al.  Clinical profiles of vitiligo in China: an analysis of 3742 patients , 2005, Clinical and experimental dermatology.

[23]  R. Spritz,et al.  Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. , 2003, Pigment cell research.

[24]  W. Westerhof,et al.  Vitiligo. Pathogenesis and treatment. , 2001, American journal of clinical dermatology.

[25]  P. Bossuyt,et al.  The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. , 1999, Archives of dermatology.

[26]  S. Handa,et al.  Vitiligo: Clinical Findings in 1436 Patients , 1999, The Journal of dermatology.

[27]  J. Nordlund The epidemiology and genetics of vitiligo. , 1997, Clinics in dermatology.

[28]  P. Majumder,et al.  Pattern of familial aggregation of vitiligo. , 1993, Archives of dermatology.

[29]  E. Keogh,et al.  Rate of Greying of Human Hair , 1965, Nature.